Compare Rivian Automotive, Inc. (RIVN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs TransMedics Group Inc — how do they compare? Rivian Automotive, Inc. trades at $13.93 (market cap $20.75B), while TransMedics Group Inc trades at $77.83 (market cap $2.74B). The key difference: Rivian Automotive, Inc. is far larger — about 7.6× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 26,144,654). Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and TransMedics Group Inc for 24 Days on average.
| RIVN | TMDX | |
|---|---|---|
Market Cap | $20.75B | $2.74B |
Volume | 26,144,654 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $150.42 |
52-Week Low | $12.50 | $61.99 |
Typical Hold Time | 61 Days | 24 Days |
Enterprise Value | $20.79B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $14.03, down 2.16% amid bearish technical signals despite beating Q3 2026 delivery estimates with 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving revenue trends and cash flow reduction. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show selling pressure with RSI near oversold levels.
Rivian presents a high-risk growth opportunity with significant operational improvements but persistent losses. The R2 SUV rollout and autonomy technology development offer long-term potential, while near-term challenges include cash burn and competitive EV market pressures. Investors should weigh improving fundamentals against substantial execution risks in a capital-intensive industry.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
